Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of Intradermally Administered ID-LV305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Next Previous
X
Search
Trial Profile

A Phase 1, Open-Label Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of Intradermally Administered ID-LV305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LV 305 (Primary)
  • Indications Advanced breast cancer; Carcinoma; Fallopian tube cancer; Male breast cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Sarcoma; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Immune Design

    • Most Recent Events

    • 12 Jun 2019 Results published in the Clinical Cancer Research
    • 04 Mar 2019 Status changed from active, no longer recruiting to completed.
    • 16 Aug 2017 Planned End Date changed from 1 Dec 2018 to 11 Aug 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top